

# Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events

Mieke Gouwy, Sofie Struyf, Samuel Noppen, Evemie Schutyser, Jean-Yves Springael, Marc Parmentier, Paul Proost, and Jo Van Damme

Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium (M.G., S.S., S.N., E.S., P.P., J.V.D.); and Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Campus Erasme, Brussels, Belgium (J.-Y.S., M.P.)

Received January 11, 2008; accepted May 9, 2008

## ABSTRACT

CC and CXC chemokines coinduced in fibroblasts and leukocytes by cytokines and microbial agents determine the number of phagocytes infiltrating into inflamed tissues. Interleukin-8/CXCL8 and stromal cell-derived factor-1/CXCL12 significantly and dose-dependently increased the migration of monocytes, expressing the corresponding CXC chemokine receptors CXCR2 and CXCR4, toward suboptimal concentrations of the monocyte chemotactic proteins CCL2 or CCL7. These findings were confirmed using different chemotaxis assays and monocytic THP-1 cells. In contrast, the combination of two CC chemokines (CCL2 plus CCL7) or two CXC chemokines (CXCL8 plus CXCL12) did not provide synergy in monocyte chemotaxis. These data show that chemokines competing for related receptors and using similar signaling pathways do not synergize. Receptor heterodimerization is probably not essen-

tial for chemokine synergy as shown in CXCR4/CCR2 cotransfectants. It is noteworthy that CCL2 mediated extracellular signal-regulated kinase 1/2 phosphorylation and calcium mobilization was significantly enhanced by CXCL8 in monocytes, indicating cooperative downstream signaling pathways during enhanced chemotaxis. Moreover, in contrast to intact CXCL12, truncated CXCL12(3–68), which has impaired receptor signaling capacity but can still desensitize CXCR4, was unable to synergize with CCL2 in monocytic cell migration. Furthermore, AMD3100 and RS102895, specific CXCR4 and CCR2 inhibitors, respectively, reduced the synergistic effect between CCL2 and CXCL12 significantly. These data indicate that for synergistic interaction between chemokines binding and signaling of the two chemokines via their proper receptors is necessary.

Tissue infiltration by leukocytes is an important phenomenon of a variety of normal as well as pathological processes, including leukocyte homing, inflammation, and cancer (Murphy et al., 2000; Strieter et al., 2006). This leukocyte recruitment is tightly regulated by the interplay

between endothelial cells and leukocytes, a process in which G protein-coupled receptor (GPCR) agonists, including complement factor C5a, bacterial peptides (e.g., fMLP), and chemokines, play a central role. Chemokines have been detected during inflammation in many tissues, suggesting that most, if not all, cell types can secrete chemokines after induction by appropriate stimuli (Gouwy et al., 2005). Thus, it is likely that more than one chemoattractant is present at the site of inflammation. These coinduced chemokines may cooperate to attract leukocytes to the site of infection, thereby enhancing the outcome of an inflammatory response. There are many different ways to enhance the cell influx mediated by chemokines. One possibility is the synergistic interaction between cytokines to induce chemokines followed by subsequent cooperation

This work was supported by the European Union 6FP EC contract INNO-CHEM, by the Interuniversity Attraction Poles Programme–Belgian State–Belgian Science Policy, the Fund for Scientific Research of Flanders (Fonds voor Wetenschappelijk Onderzoek–Vlaanderen, Belgium), the Concerted Research Actions of the Regional Government of Flanders and the Center of Excellence of the University of Leuven (Credit no. EF/05/15; Rega Institute). M.G., S.S., and E.S. are senior research assistants from the Fund for Scientific Research of Flanders.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.108.045146.

**ABBREVIATIONS:** GPCR, G protein-coupled receptor; fMLP, *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine; IFN, interferon; LPS, lipopolysaccharide; IL, interleukin; MCP, monocyte chemotactic protein; CCR, CC chemokine receptor; CHO, Chinese hamster ovary; ERK, extracellular signal-regulated kinase; PBMC, peripheral blood mononuclear cell; ConA, concanavalin A; PIC, polyriboinosinic:polyribocytidylic acid; FCS, fetal calf serum; MEM, minimal essential medium; CI, chemotactic index; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; ROI, region(s) of interest; FACS, fluorescence-activated cell sorting; PBS, phosphate-buffered saline; TLR, Toll-like receptor; RS102895, 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; AMD3100, 1,1'-(1,4-phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; PI3K, phosphatidylinositol 3-kinase.

among coinduced chemokines to further increase leukocyte recruitment (Gouwy et al., 2005). In addition, chemokines can bind to glycosaminoglycans to positively sustain a stable chemotactic gradient and hence leukocyte influx (Johnson et al., 2005). Alternatively, dampening inflammation prevents excessive tissue damage and can be mediated through post-translational modification of chemokines by proteases, resulting in impaired receptor binding and signaling capacities (Struyf et al., 2003). Furthermore, inflammatory chemokines can be trapped by chemokine decoy receptors with seven transmembrane domains and internalized by these nonsignaling receptors followed by intracellular degradation of the ligands (D'Amico et al., 2000; Mantovani et al., 2001; Nibbs et al., 2003). Finally, the expression level of functional chemokine receptors can be directly up- or down-regulated by endogenous [interferon- $\gamma$  (IFN- $\gamma$ )] or exogenous (LPS) inflammatory mediators, thereby affecting the degree of leukocyte infiltration (Sica et al., 1997; Bonecchi et al., 1999).

In an initial study, we found that CC chemokines constitutively circulating in the blood can cooperate with the inflammatory chemokine interleukin-8 (CXCL8/IL-8) in various neutrophil activation and migration tests (Struyf et al., 2001; Gouwy et al., 2002). Subsequently, the inflammatory CC chemokine monocyte chemoattractant protein-3 (CCL7/MCP-3), which is a weak neutrophil chemoattractant, was found to dose-dependently enhance the neutrophil influx toward a suboptimal concentration of CXCL8. In addition, other CC chemokines (CCL2/MCP-1 and CCL8/MCP-2) yielded a statistically significant enhancement of the neutrophil chemotactic response to low doses of CXCL8 by binding to CCR1 and/or CCR2, two receptors that are expressed on neutrophils (Gouwy et al., 2004). Moreover, we demonstrated that the constitutively circulating chemokine regakine-1, as well as the inducible CC chemokine CCL7, cooperates with inflammatory CXC chemokines, such as granulocyte chemotactic protein-2 (CXCL6/granulocyte chemotactic protein-2), to enhance the recruitment of neutrophils into the peritoneal cavity in mice (Struyf et al., 2005).

In this study, we investigated whether the synergistic interactions between chemokines can be extended to activation of other leukocyte cell types (e.g., monocytes). In particular, we describe the synergy between CC chemokines (e.g., CCL7 or CCL2) and the CXC chemokines CXCL8 or CXCL12 to chemoattract freshly isolated peripheral blood monocytes as well as the monocytic THP-1 cell line in various migration assay systems. Several lines of evidence are provided that exclude the implication of chemokine or chemokine receptor dimerization, as postulated by others for other experimental settings (Mellado et al., 2001; Paoletti et al., 2005), indicating that this synergistic effect in monocytes occurs rather at the level of intracellular signal transduction. Indeed, chemotaxis experiments using truncated CXCL12 with impaired signaling capacity, as well as chemokine receptor antagonists, indicate that each chemokine has to bind and signal through its proper receptor to cause synergistic interaction. However, evidence for post-receptor events (i.e., signal transduction) to explain synergy remains limited, although it is shown here that, in contrast to receptor transfected CHO cells, CC and CXC chemokines did cooperate to enhance the phosphorylation of ERK1/2 and calcium signaling in monocytes.

## Materials and Methods

**Reagents.** Natural human CXCL8 and CCL2 were purified to homogeneity from monocyte-derived, conditioned medium (Van Damme et al., 1989, 1997). Recombinant human CXCL12 and human CXCL8(6–77), used in the ERK phosphorylation assay, were obtained from Peprotech (Rocky Hill, NJ). Synthetic CXCL12(1–68) and CXCL12(3–68) and the CC chemokine CCL7 were synthesized by solid-phase peptide synthesis using fluorenylmethoxy-carbonyl (Fmoc) chemistry and were purified as described previously (Struyf et al., 2001). The bacterial chemotactic peptide fMLP was obtained from Sigma (St. Louis, MO). To measure chemokine production by fibroblasts, THP-1 cells and peripheral blood mononuclear cells (PBMC) cells were stimulated with a diverse set of inducers: recombinant human IFN- $\gamma$  and IL-1 $\beta$  (both from Peprotech), concanavalin A (ConA; Calbiochem, La Jolla, CA), LPS from *Escherichia coli* (0111:B4; Difco Laboratories, Detroit, MI), the double-stranded RNA polyriboinosinic:polyribocytidylic acid (polyI:rC or PIC) and phorbol 12-myristate 13-acetate (both purchased from Sigma). The CCR2 and CXCR4 antagonists RS102895 and AMD3100, respectively, were obtained from Sigma.

**Cells.** Blood was collected upon heparin, and PBMCs were isolated from granulocytes and erythrocytes by density gradient centrifugation (400g, 30 min, 15°C) on Ficoll-sodium diatrizoate (Lymphoprep; Invitrogen, Groningen, The Netherlands). Erythrocytes in the granulocyte pellet were removed by sedimentation for 30 min at 37°C in hydroxyethyl-starch solution (Plasmasteril; Fresenius AG, Bad Homburg, Germany). The remaining erythrocytes were lysed by hypotonic shock (30 s) in bidistilled water. The monocytic THP-1 cell line (American Type Culture Collection, Manassas, VA) was grown in RPMI 1640 medium (Lonza Verviers SPRL, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS; Sigma). The CHO cell line transfected with CCR2 or CXCR4 was cultured in Ham's F-12 growth medium (Lonza Verviers SPRL) enriched with 10% FCS, 400  $\mu$ g/ml G418, and 250  $\mu$ g/ml phleomycin (Zeocin; Invitrogen). The double-transfected CCR2/CXCR4/CHO cell line was cultured in Ham's F-12 growth medium enriched with 10% FCS, 400  $\mu$ g/ml G418, 250  $\mu$ g/ml phleomycin, and 5  $\mu$ g/ml blasticidin (Invitrogen) (Sohy et al., 2007). Human diploid skin/muscle-derived fibroblasts (E1SM cells) were grown in minimal essential medium (MEM; Invitrogen) containing 10% FCS.

**Chemotaxis.** Cell migration was measured in two different chemotaxis assay systems. For the classic Boyden microchamber technique (Neuro Probe, Cabin John, MD), cell fractions and samples were diluted in Hanks' balanced salt solution (Invitrogen) supplemented with 1 mg/ml human serum albumin (Belgian Red Cross, Leuven, Belgium) and tested in triplicate. The upper wells of the chamber were filled with a PBMC ( $2 \times 10^6$  cells/ml) suspension and separated from the lower wells by a 5- $\mu$ m pore-size polyvinyl pyrrolidone membrane (GE Osmonics, Minnetonka, MN). Monocytes were allowed to migrate for 2 h at 37°C. After migration, the filters were fixed and stained using Hemacolor solutions (VWR, International, Leuven, Belgium). The cells that migrated through the pores and adhered to the lower surface of the membrane were counted microscopically (500 $\times$  magnification). A chemotactic index (CI) was used to express chemotactic activity and was measured by calculating the number of cells migrated to the chemokine dilution divided by the number of cells that migrated spontaneously to the chemotaxis buffer. Synergy experiments were performed by adding two different chemokines together to the lower wells of the chamber.

The Boyden chemotaxis assay, as used in our laboratory to study the synergy between CC and CXC chemokines, is a very labor-intensive assay system involving manual microscopic cell counting. Because THP-1 cells are readily available in large numbers compared with blood monocytes, we applied a new cell migration assay with an enzymatic detection system, the Multiscreen chemotaxis assay, which makes it possible to screen the synergistic effect between chemokines on a larger scale and in a more automatic way.

The Multiscreen plate (Millipore Corporation, Billerica, MA) is a disposable device with a 96-well filter plate (5- $\mu$ m pore size) and a 96-well receiver plate. Cell migration occurs through the 96-well filter plate in response to a chemotactic gradient. The THP-1 cell suspension (100  $\mu$ l in 96-well filter plate at a concentration of  $3.5 \times 10^6$  cells/ml) and test samples (150  $\mu$ l in 96-well receiver plate) were diluted in RPMI medium without phenol red and L-glutamine (Lonza Verviers SPRL) supplemented with 0.1% BSA (endotoxin-free; Sigma). To study the effect of chemokine receptor antagonists (RS102895 and AMD3100), THP-1 cells were mixed with the antagonists before loading in the upper wells of the Multiscreen plate. After 3-h migration at 37°C, the upper 96-well filter plate was removed and the cells in the lower receiver plate were quantified using the luminescence ATP detection assay system (PerkinElmer Life and Analytical Sciences, Waltham, MA). ATP is present in all metabolically active cells, and the concentration is a value for the number of cells. This highly sensitive enzymatic ATPlite assay measures the production of light caused by the reaction of ATP, derived from the THP-1 cells after cell lysis, with added luciferase and D-luciferin. The emitted light is measured in a luminescence reader (FL600 microtiterplate fluorescence reader; Bio-Tek Instruments, Winooski, VT) and is proportional to the ATP concentration and the number of cells. The CI was calculated by dividing the luminescence value of the test sample through the luminescence value of the control buffer. Statistically significant induced chemotaxis compared with buffer was determined by the Mann-Whitney *U* test. Statistically significant differences in chemotactic indices between the combination of two chemokines and the sum of the indices obtained for the chemokines alone was determined by the Mann-Whitney *U* test.

**ERK Phosphorylation.** For the single- and double-transfected CHO cells,  $0.5 \times 10^6$  cells (in 2 ml) were seeded in a six-well plate (9 cm<sup>2</sup>; Techno Plastic Products AG, Trasadingen, Switzerland) in their corresponding Ham's F-12 growth medium. After 24 h, the growth medium was removed and the cells were cultured overnight in serum-free starvation medium. Monocytes were enriched by seeding PBMC at  $2.5 \times 10^6$  cells/ml (2 ml/well) in six-well plates in MEM without serum (starvation medium), followed by a 2-h adhesion period at 37°C. Before stimulation, the starvation medium was removed from these adherent cells (90% pure monocytes) and 900  $\mu$ l of Ham's F-12 medium or MEM supplemented with 0.5% BSA was added to each well. The cells were preincubated at 37°C for 15 min before stimulation with the test sample (diluted in 100  $\mu$ l Ham's F-12 medium or MEM supplemented with 0.5% BSA). After 2 min, signal transduction was stopped by chilling the cell culture plates on ice and adding ice-cold PBS. Afterward, cells were washed twice with ice-cold PBS, and cell lysis was performed in PBS containing 1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 6 M urea, protease inhibitor cocktail for mammalian tissues, and phosphatase inhibitor cocktails 1 and 2 (Sigma) (150  $\mu$ l/well). After 10 min, cells were scraped off and the lysate was collected, incubated for 45 min on ice and clarified (10 min, 1200g). The protein concentration in the supernatant was determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). The amount of extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in the supernatant (picograms of phospho-ERK per milligram of total protein) was determined using an ELISA for phospho-ERK1 (Thr202/Tyr204) plus phospho-ERK2 (Thr185/Tyr187) (R&D Systems, Minneapolis, MN).

**Ratiometric Imaging of Fura-2 Loaded Monocytes Using Microscopy.** Freshly purified PBMC, suspended in MEM containing 2% FBS, were allowed to adhere to four-well Lab-Tek plates (Nalge Nunc International, Rochester, NY) precoated with poly-L-lysine (Sigma) for 2 h at 37°C and 5% CO<sub>2</sub> ( $2 \times 10^6$  cells/well). Fura-2 (Invitrogen) was added at a final concentration of 2.5  $\mu$ M, 30 min before PBMC were washed to enrich for adherent monocytes. Afterward, the monocytes were washed twice with medium, twice with calcium buffer (Hanks' balanced salt solution, 1 mM Ca<sup>2+</sup>, 10 mM HEPES, and 0.1% FCS, pH 7.4) and finally 500  $\mu$ l of calcium buffer was added as working volume.

Calcium fluxes were monitored by ratiometric imaging using an Axiovert 200 M inverted microscope (Zeiss, Göttingen, Germany) equipped with a Plan-Apochromat dry objective 20 $\times$ /0.8 in combination with the Zeiss fura-2 filter set. Temperature was controlled via an XL-3 incubator. Excitation light of the high speed filter changer Lambda DG-4 (Sutter instrument Company, Novato) was switched between two filters selecting the wavelengths 340 nm and 380 nm corresponding to the maximal excitation wavelengths of calcium bound and calcium free fura-2, respectively. Emission light of 510 nm was recorded using an AxioCam MRm camera. The exposure times were fixed at 300 ms and 50 ms for the 340 nm and 380 nm excitation wavelengths, respectively, and interval settings were set at maximal speed. In each time lapse experiment, cells were stimulated after 2 min with 250  $\mu$ l of preheated (37°C) calcium buffer solution containing chemokine.

Ratio analysis on single cell level was performed with the Axiovision software release 4.6.3. Regions of interest (ROI) were drawn around 49 randomly chosen cells. After background correction, the mean ratio value for each ROI was calculated by dividing the mean pixel value of the calcium-bound fura-2 form (excitation wavelength of 340 nm) by the mean pixel value of the calcium-free fura-2 form (excitation wavelength of 380 nm). In each experiment the ratio value of each condition was normalized against the mean ratio value after stimulation of the monocytes with 3 ng/ml CCL2 (100%). Four independent experiments (different donors) were performed. In each experiment, every condition was tested at least in triplicate.

**Induction Experiments.** Fibroblast monolayers were grown to confluence in 24-well plates in MEM containing 10% FCS. Fibroblasts were stimulated for 48 h with different doses of IL-1 $\beta$  (1, 10, or 100 U/ml) or IFN- $\gamma$  (2, 20, or 200 ng/ml) or were left untreated (control). PBMCs were seeded in 24-well plates in RPMI 1640 medium supplemented with 10% FCS at a concentration of  $2 \times 10^6$  cells/ml (1 ml/well) and induced for 48 h with different doses of ConA (1 or 10  $\mu$ g/ml), LPS (0.5, 5 or 50  $\mu$ g/ml), PIC (10 or 100  $\mu$ g/ml), IL-1 $\beta$  (1, 10 or 100 U/ml), or IFN- $\gamma$  (2, 20, or 200 ng/ml) or were left untreated (control). Levels of human CXCL8 and CCL2 were quantified by specific sandwich ELISAs developed in our laboratory as described previously (Gijssbers et al., 2005).

**FACS Analysis.** THP-1 cells and PBMC were incubated and washed twice with ice-cold FACS buffer (PBS supplemented with 2% FCS). Subsequently, cells ( $0.3 \times 10^6$  cells) were labeled with 50  $\mu$ g/ml anti-CXCR4 antibody clone 12G5 (BD Pharmingen, Heidelberg, Germany), 50  $\mu$ g/ml anti-CXCR1 clone 5A12 (BD Pharmingen), 50  $\mu$ g/ml anti-CXCR2 antibody clone 48311 (R&D Systems), 50  $\mu$ g/ml anti-CCR2 antibody clone 48607 (R&D Systems), or buffer for 30 min on ice. After washing, cells were incubated with 1.3  $\mu$ g/ml phycoerythrin-conjugated goat anti-mouse IgG polyclonal antibody (BD Pharmingen) for 30 min on ice in the dark. Finally, cells were washed three times with ice-cold FACS buffer, fixed in FACS buffer containing 4% paraformaldehyde and analyzed using a FACScan flow cytometer (BD Biosciences, San Jose, CA). Monocytes were gated by their forward-scatter/side-scatter profile. It was previously confirmed that all cells within this gate are CD14<sup>+</sup>.

## Results

**CXCL8 Synergizes with CCL2 and CCL7 in Monocyte Migration.** Previous findings demonstrated that CXC and CC chemokines synergized to chemoattract neutrophils in the Boyden chamber assay. This phenomenon was further investigated in monocytes, using the same chemokines but at inverse concentration ratios. Table 1 shows that in the Boyden microchamber assay, a biologically active concentration (50 ng/ml) of CXCL8 significantly increased the monocyte chemotactic activity of CCL7 (3 and 10 ng/ml) above the additive effect of the individual chemokines. Moreover, CXCL8 dose-dependently increased the monocyte chemotac-



tic activity of the CCR2 ligand CCL2 at suboptimal concentration (0.3, 1, and 3 ng/ml) in the microchamber assay (Fig. 1A). CXCL8 alone at moderate concentration (30 ng/ml) had a weak monocyte chemotactic activity, indicating that this molecule functionally recognizes receptors expressed on monocytes. When active concentrations of CXCL8 (30 and 100 ng/ml) were added together with low concentrations of CCL2 (0.3, 1, and 3 ng/ml), the number of migrating monocytes was significantly increased above the sum of that reached with the individual chemokines (Fig. 1A). Thus, a suboptimal concentration of CC chemokine can provide a maximal monocyte influx in the abundant presence of a weakly active CXC chemokine. This cooperation between these chemokines is relevant because of the coexpression of CCR2, CXCR1, and CXCR2 on monocytes (Gerszten et al., 1999; Bonocchi et al., 2000). Indeed, FACS analysis demonstrated the presence of both CCR2 and CXCR1,2 on freshly isolated monocytes used for the chemotaxis assay (Fig. 1C). Under pathological conditions, CXC and CC chemokines can be coinduced by TLR ligands allowing synergy between these chemoattractants. Because this up-regulation can be evoked either directly by the TLR ligands (e.g., LPS, ConA or PIC) or indirectly via TLR ligands induced cytokines (e.g., IL-1 $\beta$ ), it is possible that chemokines are simultaneously present in vivo, some at high and others at low concentrations. Indeed, CXCL8 and CCL2 are often coexpressed in monocytes and fibroblasts upon stimulation with the same inflammatory mediators such as cytokines (IL-1 $\beta$  and IFN- $\gamma$ ) or TLR ligands (PIC and LPS) (Fig. 2). Moreover, CXCL12, another CXC chemokine and weak monocyte agonist, when applied at high concentrations (30, 100 and 300 ng/ml) synergized with suboptimal concentrations of CCL2 (0.3 and 1 ng/ml) to chemoattract monocytes. This is in agreement with the finding that the CXCL12 receptor CXCR4 is also expressed on monocytes (Fig. 1, B and C).

**Synergy between CC and CXC Chemokines in Monocytic THP-1 Cell Migration Using Different Chemotaxis Assay Systems.** Next, we tested the synergy between CC and CXC chemokines using the monocytic cell line THP-1. For comparison with monocytes expressing both CCR2 and CXCR4, we first confirmed the presence of these receptors on THP-1 cells by FACS analysis and calcium signaling experiments (Fig. 3A and data not shown). Both CCL2 and CXCL12 dose dependently induced THP-1 cell chemotaxis using the Boyden chamber ( $n = 2$ ), but higher concentrations (10–100 ng/ml) of CXCL12 were required compared with CCL2 (1–10 ng/ml) (Fig. 3B). Furthermore, recombinant

CXCL12 augmented the migration of THP-1 cells to suboptimal concentrations of CCL2, but to reach statistically significant effects, more experiments needed to be performed (Fig. 3B). To reach that goal we did not use the labor-intensive Boyden chemotaxis assay, but a new cell migration assay with an enzymatic read out, namely the Multiscreen chemotaxis assay, that makes it possible to screen the synergistic effect between chemokines on a larger scale. To test the synergy between CCL2 and CXCL12 on THP-1 cells, we repeatedly combined different concentrations of CCL2 (0.3, 1, and 3 ng/ml) together with multiple concentrations of CXCL12 (0.3, 1, 3, 10, and 30 ng/ml) in the lower compartment of this enzymatic 96-well plate chemotaxis assay. Figure 3C shows that in this test system, recombinant CXCL12 is almost as potent as CCL2 to chemoattract THP-1 cells. In addition, suboptimal concentrations of CXCL12 (0.3 and 1 ng/ml) significantly increased the chemotactic response of the CXCR4<sup>+</sup>/CCR2<sup>+</sup> THP-1 cells toward a suboptimal concentration of CCL2 (0.3 and 1 ng/ml) (Fig. 3C). This indicates that the phenomenon of chemokine synergy for monocyte chemotaxis can be confirmed with an alternative migration test system using a monocytic cell line. By FACS analysis, we demonstrated that during the chemotaxis assay period (3 h), CCL2 or CXCL12 did not alter the expression of CXCR4 and CCR2, respectively. As expected the chemokine CCL2 down-regulated its own receptor CCR2 on THP-1 cells (data not shown).


**Lack of Synergy between Two CC Chemokines or between Two CXC Chemokines in Monocyte Chemotaxis.** In a further attempt to precisely delineate the spectrum of synergy between chemokines for monocytic chemotaxis, the CC chemokines CCL2 and CCL7 were evaluated, using the enzymatic migration assay system, for their synergistic capacity in THP-1 chemotaxis (Fig. 4A). The CCR2 agonist CCL2 and the CCR1, CCR2, and CCR3 agonist CCL7 alone have already detectable THP-1 cell chemotactic activity at 0.3 ng/ml [e.g.,  $1.6 \pm 0.3$  and  $2.1 \pm 0.4$  (CI  $\pm$  S.E.M.), respectively]. However, these two THP-1 cell agonists were not able to synergize in the Multiscreen chemotaxis assay when tested at various concentrations (0.3, 1, and 3 ng/ml) (Fig. 4A). Indeed, a less than cumulative effect was observed when CCL2 and CCL7 were combined, maybe because of competition for CCR2 (Combadiere et al., 1995). Furthermore, the CXC chemokines CXCL8 and CXCL12 were also not able to synergize in THP-1 cell chemotaxis (Fig. 4B). The fact that 300 ng/ml CXCL8 and 3 ng/ml CXCL12 induced a weak but statistically significant THP-1 cell chemotactic activity confirms the expression of their receptors on these cells (Fig. 3A). These data show that chemokines competing for receptors using similar signaling pathways or receptors cross-regulating the functions of each other do not synergize for chemotaxis. We therefore investigated the phenomenon of synergy at the level of signal transduction.

**CC and CXC Chemokines Synergize in Signal Transduction Pathways in Normal Monocytes but Not in Chemokine Receptor Double-Transfected CHO Cells.** To further elucidate the mechanisms through which synergy among CC and CXC chemokines on monocytes occurs, direct cellular responses important for cell migration were investigated. Because it has been reported that ERK1/2 activation is involved in CCL2-mediated monocyte migration (Yen et al., 1997), we examined the involvement of this pathway in the


TABLE 1

CXCL8 synergizes with CCL7 in peripheral blood monocyte migration. CCL7 (3, 10, and 30 ng/ml) was combined with buffer or 50 ng/ml CXCL8 in the lower compartment of the Boyden microchamber to measure monocyte chemotaxis. The chemotactic response is expressed as the CI  $\pm$  S.E.M., derived from four to eight independent experiments. For statistical analysis, see *Materials and Methods*.

Chemokine	CI	P Value
Buffer +		
3 ng/ml CCL7	$2.7 \pm 1.4$	
10 ng/ml CCL7	$5.4 \pm 1.6$	
30 ng/ml CCL7	$19.3 \pm 8.8$	
50 ng/ml CXCL8 +		
0 ng/ml CCL7	$4.3 \pm 0.3$	
3 ng/ml CCL7	$13.2 \pm 2.1$	0.02
10 ng/ml CCL7	$13.7 \pm 1.1$	0.02
30 ng/ml CCL7	$27.6 \pm 5.6$	0.38




synergistic effect between CCL2 and CXCL8 on monocytes. Figure 5 shows that PBMC-derived adherent monocytes incubated for 2 min with CCL2 at 1 and 10 ng/ml induced




response is expressed as the mean chemotactic index, derived from 4 to 13 independent experiments. B, CXCL12 (30, 100, and 300 ng/ml) was combined with different concentrations of CCL2 (0.3, 1, and 3 ng/ml) in the lower compartment of the microchamber to measure monocyte chemotaxis. The chemotactic response is expressed as the mean chemotactic index, derived from 3 to 17 independent experiments. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ , statistically significant differences in chemotactic indices between the combination of two chemokines and the sum of the indices obtained for the chemokines alone, as determined by the Mann-Whitney  $U$  test. ‡,  $p < 0.01$ , statistically significant induced chemotaxis compared with buffer, as determined by the Mann-Whitney  $U$  test. C, FACS analysis for chemokine receptor expression on PBMC-derived monocytes was performed as described under *Materials and Methods*. One experiment that is representative of three is shown. The filled curves represent the staining by the chemokine-receptor specific monoclonal antibody. The open curves represent the background staining with secondary antibody only.

response is expressed as the mean chemotactic index, derived from 4 to 13 independent experiments. B, CXCL12 (30, 100, and 300 ng/ml) was combined with different concentrations of CCL2 (0.3, 1, and 3 ng/ml) in the lower compartment of the microchamber to measure monocyte chemotaxis. The chemotactic response is expressed as the mean chemotactic index, derived from 3 to 17 independent experiments. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ , statistically significant differences in chemotactic indices between the combination of two chemokines and the sum of the indices obtained for the chemokines alone, as determined by the Mann-Whitney  $U$  test. ‡,  $p < 0.01$ , statistically significant induced chemotaxis compared with buffer, as determined by the Mann-Whitney  $U$  test. C, FACS analysis for chemokine receptor expression on PBMC-derived monocytes was performed as described under *Materials and Methods*. One experiment that is representative of three is shown. The filled curves represent the staining by the chemokine-receptor specific monoclonal antibody. The open curves represent the background staining with secondary antibody only.



**Fig. 3.** Synergy between CXCL12 and CCL2 in THP-1 cell migration using different chemotaxis assay systems. **A**, FACS analysis for chemokine receptor expression in THP-1 cells was performed as described under *Materials and Methods*. One representative experiment of three is shown. The filled curves represent the staining by the chemokine receptor-specific monoclonal antibody. The open curves represent the background staining with secondary antibody only. **B**, recombinant CXCL12

significant phosphorylation of ERK1/2 protein compared with buffer-treated cells ( $p = 0.007$  and  $0.0002$ , respectively). In contrast to CCL2, treatment with recombinant CXCL8(6–77) (50 and 500 ng/ml) did not lead to a significant ERK1/2 activation in monocytes. Furthermore, when monocytes were incubated for 2 min with combinations of different concentrations of CCL2 (0.1, 1, and 10 ng/ml) and CXCL8(6–77) (50




**Fig. 4.** Lack of synergy between CC (CCL2 and CCL7) chemokines or between CXC (CXCL8 and CXCL12) chemokines in monocytic THP-1 cell chemotaxis. CCL7 (0.3, 1, and 3 ng/ml) and CCL2 (0.3, 1, and 3 ng/ml) (**A**) or CXCL8 (0.3, 3, 30, and 300 ng/ml) and CXCL12 (0.3, 1, and 3 ng/ml) (**B**) were combined in the lower compartment of the enzymatic Multiscreen chemotaxis assay to measure THP-1 cell chemotaxis. The chemotactic response is expressed as the mean CI, derived from five to nine independent experiments. †,  $p < 0.05$ ; ‡,  $p < 0.01$ , statistically significant induced chemotaxis compared with buffer, as determined by the Mann-Whitney  $U$  test.

(0–300 ng/ml) was combined with different concentrations of CCL2 (0–10 ng/ml) in the lower compartment of the Boyden microchamber to measure THP-1 cell chemotaxis. The chemotactic response is expressed as the mean CI, derived from two independent experiments. **C**, different concentrations of CCL2 (0–3 ng/ml) were combined with multiple concentrations of recombinant CXCL12 (0–30 ng/ml) in the lower compartment of the enzymatic Multiscreen chemotaxis assay to measure THP-1 cell chemotaxis. The chemotactic response is expressed as the mean CI, derived from 3 to 10 independent experiments. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ , statistically significant differences in chemotactic indices between the combination of two chemokines and the sum of the indices obtained for the chemokines alone, as determined by the Mann-Whitney  $U$  test. †,  $p < 0.01$ , statistically significant induced chemotaxis compared with buffer, as determined by the Mann-Whitney  $U$  test.


and 500 ng/ml), synergy was observed in ERK1/2 phosphorylation, in agreement with the fact that CCL2 synergizes with CXCL8 in monocyte migration (Fig. 1A). Indeed, the combination of 50 ng/ml CXCL8(6–77) with 10 ng/ml CCL2 significantly ( $p = 0.043$ ) enhanced the phosphorylation of ERK1/2 compared with the ERK1/2 phosphorylation induced by CCL2 alone. Next, we investigated whether at other time points (5, 10, and 20 min) CCL2 and CXCL8 were also able to synergize to induce ERK phosphorylation in monocytes. In contrast to CXCL8, CCL2 induced significant phosphorylation of ERK1/2 in monocytes after incubation of the cells during 5, 10, and 20 min, compared with buffer-treated cells. Incubation of the monocytes with a combination of CCL2 (10 ng/ml) and CXCL8(6–77) (50 ng/ml) for 5 min also provided enhanced ERK phosphorylation compared with incubation of the monocytes with CCL2 alone. However, when the monocytes were incubated during 10 and 20 min with a combination of CCL2 and CXCL8, no enhancement in ERK phosphorylation was observed compared with CCL2-treated cells. We can conclude that the synergistic effect on ERK phosphorylation is time point dependent (data not shown). Furthermore, we investigated whether a combination of CCL2 and CXCL12 can enhance the ERK1/2 phosphorylation in nonhematopoietic cells transfected with a single chemokine receptor (i.e., CHO/CXCR4 or CHO/CCR2) or in double-transfected CXCR4/CCR2/CHO cells (Fig. 6 and data not shown). CXCL12 (3, 30, and 300 ng/ml) and CCL2 (1, 10, and 100 ng/ml) induced significant ERK1/2 phosphorylation within 5 min in CHO/CXCR4 and CHO/CCR2 cells, respectively, compared with buffer-treated cells. However, no synergy in the ERK1/2 signaling pathway could be observed in the cell lysates of CHO/CXCR4 and CHO/CCR2 cells when the cells were incubated during 5 min with different concentrations of CXCL12 in combination with CCL2 (Fig. 6A and data not shown). Moreover, CXCL12 (0.3, 3, 30 and 300 ng/ml) and CCL2 (0.3, 3, 30 and 300 ng/ml) did not cooperate to enhance the phosphorylation of ERK1/2 in double-transfected CXCR4/

CCR2/CHO cells (Fig. 6B). We can conclude that ERK1/2 phosphorylation induced by CCL2 can be significantly enhanced by CXCL8 in monocytes. In contrast, the synergistic effect in ERK1/2 phosphorylation observed on monocytes does not occur in single- or double-transfected CHO cells. This discrepancy can occur because GPCR-transfected nonhematopoietic cells might miss essential mediators to allow synergy in one or more signaling pathways.

**CC and CXC Chemokines Synergize in Calcium Signaling in Monocytes.** Many chemokines induce a rapid elevation of the cytosolic calcium level after binding to their GPCR. Using the single cell calcium assay, we demonstrated that CCL2 (3 and 10 ng/ml) was capable of triggering a detectable calcium signal in adherent monocytes. Indeed, the mean ratio value after stimulation of the monocytes with 3 and 10 ng/ml CCL2 was 0.07 and 0.12, respectively (Fig. 7A and data not shown). To investigate the synergy between CCL2 and CXCL8 in the single-cell calcium assay on monocytes, we normalized in each experiment the ratio value of each condition against the mean ratio value after stimulation




**Fig. 5.** Synergy between CC and CXC chemokines in the ERK1/2 pathway in monocytes. PBMC-derived adherent monocytes were stimulated with different concentrations of CCL2 (0.1, 1, and 10 ng/ml), recombinant CXCL8(6–77) (50 and 500 ng/ml) or a combination of CCL2 and CXCL8(6–77). The level of ERK1/2 phosphorylation in the cell lysate was determined by ELISA for phospho-ERK1/2. The mean values and S.E.M. are derived from 5 to 12 independent experiments. Statistically significant ERK1/2 phosphorylation induced by CCL2 compared with medium-treated cells determined by the Mann-Whitney  $U$  test is indicated ( $\ddagger$ ,  $p < 0.01$ ). Statistically significant differences in ERK1/2 phosphorylation between the combination of CCL2 and CXCL8(6–77) and the ERK1/2 phosphorylation induced by CCL2 alone, determined by the Sign test, are indicated by asterisks (\*,  $p < 0.05$ ).



**Fig. 6.** Failure of CC and CXC chemokines to synergize in the ERK1/2 pathway in CHO/CXCR4 or CHO/CCR2/CXCR4 cells. Serum-starved CXCR4 (A) or CCR2/CXCR4 double-transfected (B) CHO cells were stimulated with different concentrations of CXCL12 or CCL2 or a combination of CXCL12 and CCL2. The level of ERK1/2 phosphorylation in the cell lysate was determined by ELISA for phospho-ERK1/2. The mean values are derived from one to four independent experiments.





**Fig. 7.** CCL2 and CXCL8 synergize in calcium signaling in monocytes. Adherent PBMC-derived monocytes were loaded with FURA-2, washed, and stimulated with CCL2 (3 ng/ml), CXCL8 (100 ng/ml), or a combination of CCL2 (3 ng/ml) and CXCL8 (100 ng/ml). A: One representative experiment is shown of four independent experiments. The ratio value for each ROI was calculated by dividing the mean pixel value of the calcium bound FURA-2 form by the mean pixel value of the calcium free FURA-2 form. B, data are represented as box and whisker plots in which the small squares indicate the median value of a group. The box is outlined

of the monocytes with 3 ng/ml CCL2 (= 100%) (Fig. 7B). Simultaneous stimulation of monocytes with CCL2 (3 ng/ml) and CXCL8 (100 ng/ml) significantly enhanced the single cell intracellular calcium response compared with CCL2 alone, indicating that this signaling pathway is involved in the synergy between CC and CXC chemokines in monocyte chemotaxis. Indeed, the mean ratio value after stimulation of the monocytes with a combination of CCL2 (3 ng/ml) and CXCL8 (100 ng/ml) was 211%, whereas the ratio value after stimulation of the cells with CCL2 and CXCL8 alone was 100 and 40%, respectively (Fig. 7B).

**Effect of Proteolytic Processing of Chemokines on Synergy in Monocyte Chemotaxis.** To further elucidate the implication of chemokine specific receptor signaling in the synergy between GPCR ligands in chemotaxis, experiments were performed using intact and NH<sub>2</sub>-terminally truncated chemokines with impaired receptor signaling capacity. For this purpose, either intact CXCL12 or CXCL12 lacking the NH<sub>2</sub>-terminal dipeptide was used in combination with CCL2. In contrast to intact CXCL12, the truncated form did not induce a calcium response in CHO/CXCR4 cells (Table 2) (Gouwy et al., 2004). Moreover, truncated CXCL12-(3–68) only partially desensitized the calcium mobilizing capacity of intact CXCL12 indicating its impaired CXCR4 signaling capacity. Next, it was shown that the truncated CXCL12(3–68) was not able to synergize with CCL2 in the THP-1 cell Multiscreen migration test, whereas intact synthetic CXCL12 did (Fig. 3C and Fig. 8). These data suggest that, to obtain synergy, two chemokines must bind and signal via their proper receptor (Gouwy et al., 2004).

**The Synergistic Effect between CCL2 and CXCL12 in THP-1 Cell Chemotaxis Is Inhibited by Receptor Specific Antagonists.** To demonstrate that the synergy between CCL2 and CXCL12 in THP-1 cell chemotaxis implies receptor mediated events, the combination of CCL2 and CXCL12 was evaluated in the Multiscreen chemotaxis assay in the presence of their receptor specific antagonists RS102895 (CCR2) and AMD3100 (CXCR4) (Fig. 9). The chemotactic effect of CCL2 (1 ng/ml) and CXCL12 (2 ng/ml) alone was blocked [ $36.3 \pm 13.5$  and  $47.3 \pm 8.6$  (mean percentage inhibition  $\pm$  S.E.M.) respectively] in the presence of RS102895 and AMD3100, respectively. RS102895 (1  $\mu$ M) as well as AMD3100 (1  $\mu$ g/ml) significantly reduced ( $p = 0.02$  and  $0.0064$ , respectively) the synergistic effect between CCL2 (1 ng/ml) and CXCL12 (2 ng/ml) observed in the absence of receptor antagonist. Thus, it seems that both chemokine receptors are implicated in the synergistic effect of chemokines on monocytic cell migration.

## Discussion

Chemokines constitute a family of GPCR binding proteins, each acting on a selective set of target cells, predominantly

by the first quartile at the bottom and the third quartile at the top and encloses the middle 50% of the data (interquartile range). Whiskers extend to the nonoutlier range of the data set. Circles depict outliers, with a value  $>1.5$  times the interquartile range. The ratio value was calculated for each condition and normalized against the ratio value after stimulation of the monocytes with 3 ng/ml CCL2 (100%). Four different experiments were performed. Statistically significant difference between the calcium increase after stimulation with the combination of CCL2 and CXCL8 and the calcium increase induced by CCL2 alone, determined by the Sign test, is indicated by asterisks (\*,  $p < 0.05$ ).



leukocytes, defined by their receptor specificity. In vitro induction of chemokines by cytokines or TLR ligands has been reported for various cell types. This induction pattern can be chemokine-specific depending on both the cell type and the precise stimuli (Gouwy et al., 2005). In vivo microbial infection triggers production of many chemokines simultaneously either directly in response to TLR ligands or indirectly to induced inflammatory cytokines, which might act synergistically. As an additional dimension, cooperation between chemokines to enhance the inflammatory response should also be considered. Indeed, we previously showed that suboptimal concentrations of the neutrophil chemoattractant CXCL8 synergized with high concentrations of monocyte attracting CC chemokines (e.g., CCL2 or CCL7) to enhance neutrophil migration (Gouwy et al., 2004). In this study, we show that CXCL8 and CXCL12 significantly increase the chemotactic response of monocytes toward a suboptimal concentration of CCL2 or CCL7. In contrast, the combination of two CC chemokines (i.e., CCL2 and CCL7) or two CXC chemokines (i.e., CXCL8 and CXCL12) did not provide synergy in monocyte chemotaxis. These data show that chemokines competing for identical receptors or for different GPCR but using similar signaling pathways (e.g., CCL2 and CCL7) or for receptors cross-regulating the functions of each other (e.g., CXCR1 and CXCR4) do not synergize for chemotaxis. Indeed, CCL7 probably uses the same receptor CCR2 and signal transduction pathways as CCL2 in monocytes, because CCL2 cross-desensitizes the calcium and chemotactic response of CCL7 and vice versa in these cells (Sozzani et al., 1994, 1995). Moreover, CXCL8 activation of CXCR1 cross-phosphorylates CXCR4 and cross-desensitizes the responsiveness of monocytes to CXCL12 (Richardson et al., 2003). This desensitization between chemokine receptors could explain the lack of synergy between CCL7 and CCL2 or between CXCL8 and CXCL12 in monocytic cell migration. From these observations, it must be deduced that synergy between chemokines is not a general phenomenon and exists only for specific chemokine pairs on specific leukocyte types.

The cellular mechanisms involved in chemokine synergy to attract monocytes have not been investigated in detail and the suggested mode of action for synergy to attract other leukocytes or receptor-transfected cells are not concurrent. Some studies claimed that chemokine or receptor dimerization may be implicated in the synergistic effect between chemokines (Mellado et al., 2001; Paoletti et al., 2005, Sebastiani et al., 2005). Simultaneous stimulation of PBMC with CCL2 and CCL5 induced the formation of CCR2/CCR5 heterodimers and enhanced the calcium signal and chemotactic response compared with addition of these chemokines alone

(Mellado et al., 2001). In contrast, El-Asmar et al. (2005) did not observe such a synergistic effect between these chemokines in calcium signaling upon costimulation of CCR5 and CCR2 expressed in CHO cells, whereas Springael et al. (2006) found a negative binding cooperativity. We observed that simultaneous stimulation of monocytes with CCL2 and CXCL8 did enhance the intracellular calcium signal monitored at single-cell level, indicating that this signaling pathway is involved in the synergy between CC and CXC chemokines. Sohy et al. (2007) observed GPCR heterodimers formed by CCR2 and CXCR4 in primary leukocytes. However, chemotaxis experiments with activated CD4<sup>+</sup> T lymphocytes showed that migration toward CXCL12 or a combination of CXCL12 and CCL2 at equimolar concentrations was similar (Sohy et al., 2007). To further elucidate the mechanism of the synergistic effect between CCL2 and CXCL12 at the receptor binding and signaling level, we performed chemotaxis experiments using intact CXCL12 or CXCL12(3–68) lacking the NH<sub>2</sub>-terminal dipeptide, hence exerting weak chemotactic activity. In contrast to the intact CXCL12, the truncated CXCL12(3–68) was not able to synergize with CCL2 in THP-1 cell migration. Because CXCL12(3–68) has impaired signaling capacity through CXCR4 compared with CXCL12, these data corroborate with our previous findings that, to obtain neutrophil synergy, binding, and signaling of the two chemokines to their proper receptor, is most likely necessary (Gouwy et al., 2004). These findings are different from those obtained with a CCR4- or CCR7-transfected murine pre-B cell line, in which a single receptor type was reported to be sufficient for synergy between two chemokines recognizing different receptors (Paoletti et al., 2005; Sebastiani et al., 2005). Furthermore, the specific CCR2 and CXCR4 inhibitors RS102895 and AMD3100, inhibited the synergistic effect between CCL2 and CXCL12, indicating that this phenomenon implies receptor mediated events.

Another possible mechanism of the cooperation between chemokines is synergy between these mediators at the level of intracellular signal transduction. Chemokines bind to their GPCR to trigger multiple independent signal transduction pathways (Neel et al., 2005). Although, several reports demonstrated that CCL2 can affect several secondary messengers (Dubois et al., 1996; Cambien et al., 2001), data concerning the exact relationships between these different signaling cascades and their impact on the migratory response are conflicting (Ashida et al., 2001; Jiménez-Sainz et al., 2003). For instance, Yen et al. (1997) demonstrated that MCP-1 induced rapid and transient activation of ERK1/2 in human monocytes and in CHO cells expressing CCR2 and


TABLE 2

Desensitization of Ca<sup>2+</sup> response induced in CHO/CXCR4 cells by synthetic intact versus truncated CXCL12


Results shown are the mean of two experiments, intracellular calcium responses were determined as described in Gouwy et al. (2004). Inhibition indicates the percentage inhibition of the second stimulus by the first stimulus.

First Stimulus		Second Stimulus		Inhibition
Chemokine	Increase in [Ca <sup>2+</sup> ] <sub>i</sub>	Chemokine	Increase in [Ca <sup>2+</sup> ] <sub>i</sub>	
	nM		nM	%
CXCL12(1–68) 10 ng/ml	304	10 ng/ml CXCL12(1–68)	63	79
CXCL12(3–68) 100 ng/ml	0	10 ng/ml CXCL12(1–68)	323	0
CXCL12(3–68) 300 ng/ml	0	10 ng/ml CXCL12(1–68)	368	0
CXCL12(3–68) 1 μg/ml	0	10 ng/ml CXCL12(1–68)	166	45
CXCL12(3–68) 3 μg/ml	0	10 ng/ml CXCL12(1–68)	72	76

that an inhibitor of ERK1/2 (i.e., PD980959) impaired the CCL2-induced chemotaxis of these cells. The same inhibitory effect on cell migration was observed for the PI3K inhibitor wortmannin, although this compound was not effective in the prevention of ERK1/2 activation. These data were further confirmed by Wain et al. (2002) who have shown that an inhibitor of mitogen-activated protein kinase kinase activation significantly inhibited the CCL2-mediated chemotaxis. Moreover, wortmannin also partially inhibited the CCL2-induced chemotaxis, although this inhibitor did not significantly inhibit ERK1/2 activation. These data suggest the existence of a coordinated action of multiple independent



**Fig. 8.** NH<sub>2</sub>-terminal processing of CXCL12 impairs synergy with CCL2 in monocyte chemotaxis. Different concentrations of CCL2 (0.3, 1, and 3 ng/ml) were combined with multiple concentrations of synthetic CXCL12(1–68) (1 or 10 ng/ml) or synthetic CXCL12(3–68) (1, 30, or 300 ng/ml) in the lower compartment of the enzymatic Multiscreen chemotaxis assay to measure THP-1 cell chemotaxis. The chemotactic response is expressed as the mean CI, derived from four independent experiments. †,  $p < 0.05$ , statistically significant induced chemotaxis compared with buffer, as determined by the Mann-Whitney  $U$  test.



**Fig. 9.** Inhibition of the synergistic effect between CCL2 and CXCL12 by chemokine receptor antagonists. CCL2 (1 ng/ml), CXCL12 (2 ng/ml), and CCL2 (1 ng/ml) plus CXCL12 (2 ng/ml) were added in the lower compartment of the enzymatic Multiscreen chemotaxis assay to measure THP-1 cell chemotaxis. RS102895 (1  $\mu$ M), AMD3100 (1  $\mu$ g/ml), or buffer was added to the cells just before loading in the upper compartment of the Multiscreen plate. The chemotactic response is expressed as the mean CI, derived from six independent experiments. The combination of CCL2 and CXCL12 resulted in a significant ( $p = 0.03$ ) increase in chemotactic index. The statistically significant reductions in synergy between CCL2 and CXCL12 in the presence of RS102895 and AMD3100 are determined by the Mann-Whitney  $U$  test and are indicated by an asterisk (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ). The statistically significant inhibition of the chemotactic activity of CCL2 or CXCL12 in the presence of RS102895 or AMD3100 are determined by the Mann-Whitney  $U$  test and are indicated as †,  $p < 0.01$ .

signal transduction pathways to induce chemokine-mediated chemotaxis (Cambien et al., 2001). On the contrary, according to Fine et al. (2001), neither PI3K nor ERK1/2 activity was required for monocyte migration toward CCL2, because pretreatment of monocytes with wortmannin or PD980959, respectively, had no effect on the chemotactic response. In this study we confirmed that CCL2 induces phosphorylation of ERK1/2 in monocytes. Moreover, ERK1/2 phosphorylation induced by CCL2 can be significantly enhanced by CXCL8 in monocytes. In contrast, the synergistic effect in ERK1/2 phosphorylation observed in monocytes does not occur in single CCR2- or CXCR4- or in CCR2/CXCR4 double-transfected CHO cells treated with a combination of CCL2 and CXCL12. This suggests that the synergy in chemotaxis is dependent on signaling pathways that are not functional in these transfectants. Indeed, this may be due to the different availability of certain G protein subunits or the expression level of other downstream mediators in different cell types. Arai et al. (1996) demonstrated that in transfected COS-7 cells, CCR2 was coupled to  $G_{\alpha_i}$ ,  $G_{\alpha_q}$ , and  $G_{\alpha_{16}}$ , whereas in transfected HEK-293 cells, CCR2 was coupled to  $G_{\alpha_q}$  but failed to couple to  $G_{\alpha_{16}}$ . Nevertheless, Sebastiani et al. (2005) observed such a synergistic effect in ERK1/2 phosphorylation after costimulation of single CCR4-transfected murine pre-B cell line with the CCR4 ligand CCL22 in combination with CXCL10. Moreover, CXCL13, which on its own did not lead to ERK1/2 activation in CCR7-transfected murine pre-B cells, synergistically augmented the phosphorylation of ERK1/2 induced by suboptimal concentrations of CCL21 (Paoletti et al., 2005). It needs to be emphasized that these latter studies used a receptor expression system. In a physiologically more relevant observation, the synergistic effect between C3a and CXCL12 to promote the homing of hematopoietic progenitor cells to the bone marrow was not mediated by the CXCL12-dependent activation of the ERK1/2 or PI3K signal transduction pathway (Reca et al., 2003). Finally, it cannot be excluded that minimally enhanced multiple signaling pathways each contributes in part to provoke a concerted synergistic chemotactic response.

Chemokines play a complex role in various inflammatory diseases, and the apparent redundancy in their expression requires improved concepts defining the cooperation of chemokines in regulating the recruitment of mononuclear cells (Weber et al., 2004). Both the chemokine concentration and the presence of a cooperating chemokine determine the number of mononuclear cells that will infiltrate the inflamed tissue. It can be concluded that the receptor signal transducing capacity must remain unaffected to guarantee chemokine synergy at inducing cell migration. As a consequence, proteolytic processing of chemokines during the inflammatory response leads not only to impaired chemotaxis but also to incapability to synergize with other chemokines. This double negative feedback loop is even further reinforced by the fact that by their residual receptor binding capacity, truncated chemokines antagonize intact chemokines by competing for receptor binding. The synergy between chemokines in leukocyte migration may enhance an inflammatory response. As a consequence, antagonization of a single chemokine may down-modulate immune responses, because of the inhibitory effect on its synergy with other chemokines.

## Acknowledgments

We thank the members of the Blood Transfusion Center of Leuven for providing buffy coats. The assistance of J. Vandercappellen, R. Conings, J.-P. Lenaerts, and K. Cornelis are greatly appreciated.

## References

- Arai H and Charo IF (1996) Differential regulation of G-protein-mediated signaling by chemokine receptors. *J Biol Chem* **271**:21814–21819.
- Ashida N, Arai H, Yamasaki M, and Kita T (2001) Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis. *J Biol Chem* **276**:16555–16560.
- Bonecchi R, Polentarutti N, Luini W, Borsatti A, Bernasconi S, Locati M, Power C, Proudfoot A, Wells TN, Mackay C, et al. (1999) Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN- $\gamma$  in human neutrophils. *J Immunol* **162**:474–479.
- Bonecchi R, Facchetti F, Dusi S, Luini W, Lissandrini D, Simmelink M, Locati M, Bernasconi S, Allavena P, Brandt E, et al. (2000) Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. *J Immunol* **164**:3862–3869.
- Cambien B, Pomeranz M, Millet MA, Rossi B, and Schmid-Alliana A (2001) Signal transduction involved in MCP-1 mediated monocytic transendothelial migration. *Blood* **97**:359–366.
- Combadiere C, Ahuja SK, Van Damme J, Tiffany HL, Gao JL, and Murphy PM (1995) Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. *J Biol Chem* **270**:29671–29675.
- D'Amico G, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A, Sozzani S, Allavena P, and Mantovani A (2000) Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. *Nat Immunol* **1**:387–391.
- Dubois PM, Palmer D, Webb ML, Ledbetter JA, and Shapiro RA (1996) Early signal transduction by the receptor to the chemokine monocyte chemoattractant protein-1 in a murine T cell hybrid. *J Immunol* **156**:1356–1361.
- El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, and Parmentier M (2005) Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. *Mol Pharmacol* **67**:460–469.
- Fine JS, Byrnes HD, Zavodny PJ, and Hipkin RW (2001) Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis. *Inflammation* **25**:61–67.
- Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, and Rosenzweig A (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature* **398**:718–723.
- Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G, Penninx F, Ectors N, Geboes K, and Van Damme J (2005) GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal disorders. *Exp Cell Res* **303**:331–342.
- Gouwy M, Struyf S, Mahieu F, Put W, Proost P, and Van Damme J (2002) The unique property of the CC chemokine regakine-1 to synergize with other plasma-derived inflammatory mediators in neutrophil chemotaxis does not reside in its NH<sub>2</sub>-terminal structure. *Mol Pharmacol* **62**:173–180.
- Gouwy M, Struyf S, Catusse J, Proost P, and Van Damme J (2004) Synergy between pro-inflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. *J Leukoc Biol* **76**:185–194.
- Gouwy M, Struyf S, Proost P, and Van Damme J (2005) Synergy in cytokine and chemokine networks amplifies the inflammatory response. *Cytokine Growth Factor Rev* **16**:561–580.
- Jiménez-Sainz MC, Fast B, Mayor F Jr, and Aragay AM (2003) Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. *Mol Pharmacol* **64**:773–782.
- Johnson Z, Proudfoot AE, and Handel TM (2005) Interaction of chemokines and glycosaminoglycans: A new twist in the regulation of chemokine function with opportunities for therapeutic intervention. *Cytokine Growth Factor Rev* **16**:625–636.
- Mantovani A, Locati M, Vecchi A, Sozzani S, and Allavena P (2001) Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. *Trends Immunol* **22**:328–336.
- Mellado M, Rodríguez-Frade JM, Vila-Coro AJ, Fernández S, Martín de Ana A, Jones DR, Torán JL, and Martínez-A C (2001) Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. *EMBO J* **20**:2497–2507.
- Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev* **52**:145–176.
- Neel NF, Schutysse E, Sai J, Fan GH, and Richmond A (2005) Chemokine receptor internalization and intracellular trafficking. *Cytokine Growth Factor Rev* **16**:637–658.
- Nibbs R, Graham G, and Rot A (2003) Chemokines on the move: control by the chemokine “interceptors” Duffy blood group antigen and D6. *Semin Immunol* **15**:287–294.
- Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Ugucioni M, and Gerber BO (2005) A rich chemokine environment strongly enhances leukocyte migration and activities. *Blood* **105**:3405–3412.
- Reca R, Mastellos D, Majka M, Marquez L, Ratajczak J, Franchini S, Glodek A, Honczarenko M, Spruce LA, Janowska-Wieczorek A, et al. (2003) Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. *Blood* **101**:3784–3793.
- Richardson RM, Tokunaga K, Marjoram R, Sata T, and Snyderman R (2003) Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity. *J Biol Chem* **278**:15867–15873.
- Sebastiani S, Danelon G, Gerber B, and Ugucioni M (2005) CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first  $\beta$ -strand of chemokine. *Eur J Immunol* **35**:746–756.
- Sica A, Saccani A, Borsatti A, Power CA, Wells TN, Luini W, Polentarutti N, Sozzani S, and Mantovani A (1997) Bacterial lipopolysaccharide rapidly inhibits expression of CC chemokine receptors in human monocytes. *J Exp Med* **185**:969–974.
- Sohy D, Parmentier M, and Springael JY (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. *J Biol Chem* **282**:30062–30069.
- Sozzani S, Zhou D, Locati M, Rieppi M, Proost P, Magazin M, Vita N, van Damme J, and Mantovani A (1994) Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. *J Immunol* **152**:3615–3622.
- Sozzani S, Locati M, Zhou D, Rieppi M, Luini W, Lamorte G, Bianchi G, Polentarutti N, Allavena P, and Mantovani A (1995) Receptors, signal transduction and spectrum of action of monocyte chemotactic protein-1 and related chemokines. *J Leukoc Biol* **57**:788–794.
- Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, and Parmentier M (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. *Mol Pharmacol* **69**:1652–1661.
- Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, and Belperio JA (2006) Cancer CXC chemokine networks and tumour angiogenesis. *Eur J Cancer* **42**:768–778.
- Struyf S, Proost P, Lenaerts JP, Stoops G, Wuyts A, and Van Damme J (2001) Identification of a blood-derived chemoattractant for neutrophils and lymphocytes as a novel CC chemokine, regakine-1. *Blood* **97**:2197–2204.
- Struyf S, Proost P, and Van Damme J (2003) Regulation of the immune response by the interaction of chemokines and proteases. *Adv Immunol* **81**:1–44.
- Struyf S, Gouwy M, Dillen C, Proost P, Opdenakker G, and Van Damme J (2005) Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. *Eur J Immunol* **35**:1583–1591.
- Van Damme J, Van Beeumen J, Conings R, Decock B, and Billiau A (1989) Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of beta-thromboglobulin. *Eur J Biochem* **181**:337–344.
- Van Damme J, Struyf S, Wuyts A, Opdenakker G, Proost P, Allavena P, Sozzani S, and Mantovani A (1997) Isolation of human monocyte chemotactic proteins and study of their producer and responder cells by immunotests and bioassays, in *Methods Enzymology* (Horuk R ed) volume 287, pp 109–127, Academic Press, San Diego, CA.
- Wain JH, Kirby JA, and Ali S (2002) Leukocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. *Clin Exp Immunol* **127**:436–444.
- Weber C, Schober A, and Zernecke A (2004) Chemokines. Key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. *Arterioscler Thromb Vasc Biol* **24**:1997–2008.
- Yen H, Zhang Y, Penfold S, and Rollins BJ (1997) MCP-1 mediated chemotaxis requires activation of non-overlapping signal transduction pathways. *J Leukoc Biol* **61**:529–532.

**Address correspondence to:** Prof. Jo Van Damme, Laboratory of Molecular Immunology, Rega Institute, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: jo.vandamme@rega.kuleuven.be.